Back to Search
Start Over
Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells.
- Source :
-
Theranostics [Theranostics] 2021 Jan 01; Vol. 11 (3), pp. 1295-1309. Date of Electronic Publication: 2021 Jan 01 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Background: Immunosuppressive tumor microenvironment (TME) in glioblastoma (GBM) is one of the contributing factors for failed immunotherapies. Therefore, there is an urgent need to better understand TME and to identify novel modulators of TME for more effective GBM therapies. We hypothesized that H <superscript>+</superscript> extrusion protein Na/H exchanger 1 (NHE1) plays a role in dysregulation of glucose metabolism and immunosuppression of GBM. We investigated the efficacy of blockade of NHE1 activity in combination with temozolomide (TMZ) therapy in increasing anti-tumor immunity. Methods: Mouse syngeneic intracranial glioma model was used to test four treatment regimens: DMSO (Vehicle-control), TMZ, NHE1 specific inhibitor HOE642, or TMZ+HOE642 (T+H) combination. Ex vivo <superscript>1</superscript> H/ <superscript>19</superscript> Fluorine magnetic resonance imaging (MRI) with cell tracking agent Vsense was performed to monitor the infiltration of glioma-associated microglia/myeloid cells (GAMs). Glucose metabolism and transcriptome profiles were analyzed by Seahorse analyzer and bulk RNA-sequencing. The impact of selective Nhe1 deletion in GAMs on sensitivity to anti-PD-1 therapy was evaluated in transgenic NHE1 knockout ( KO ) mice. Results: Among the tested treatment regimens, the T+H combination therapy significantly stimulated the infiltration of GAMs and T-cells; up-regulated Th1 activation, and mitochondrial oxidative phosphorylation (OXPHOS) pathway genes, increased glucose uptake and mitochondrial mass, and decreased aerobic glycolysis in GAMs. Selective deletion of Nhe1 in Cx3cr1 <superscript>+</superscript> Nhe1 KO mice increased anti-tumor immunity and sensitivity to TMZ plus anti-PD-1 combinatorial therapy. Conclusions: NHE1 plays a role in developing glioma immunosuppressive TME in part by dysregulating glucose metabolism of GAMs and emerges as a therapeutic target for improving glioma immunity.<br />Competing Interests: Competing Interests: The authors have declared that no competing interest exists.<br /> (© The author(s).)
- Subjects :
- Animals
Cell Line, Tumor
Disease Models, Animal
Female
Glioma metabolism
Glucose metabolism
Immune Tolerance drug effects
Immunotherapy methods
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Mice, Transgenic
Microglia drug effects
Microglia immunology
Mitochondria drug effects
Mitochondria metabolism
Myeloid Cells immunology
Myeloid Cells metabolism
Temozolomide pharmacology
Th1 Cells drug effects
Tumor Microenvironment drug effects
Up-Regulation drug effects
Brain Neoplasms drug therapy
Brain Neoplasms immunology
Glioma drug therapy
Glioma immunology
Myeloid Cells drug effects
Oxidative Phosphorylation drug effects
Sodium-Hydrogen Exchanger 1 antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1838-7640
- Volume :
- 11
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Theranostics
- Publication Type :
- Academic Journal
- Accession number :
- 33391535
- Full Text :
- https://doi.org/10.7150/thno.50150